Last reviewed · How we verify
Other anti-HBV medication
At a glance
| Generic name | Other anti-HBV medication |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants (PHASE2)
- Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children (PHASE2)
- The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation
- Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
- Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV (PHASE4)
- Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other anti-HBV medication CI brief — competitive landscape report
- Other anti-HBV medication updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI